Appointment
Appointed as a Non-Executive Director in April 2026. Harry will join the Audit Committee from May 2026.
Career
Harry was CFO of Novartis from April 2013 until retiring in March 2026, having joined in 2003. Prior to that, he spent 13 years at Procter & Gamble in various finance roles. He was a Non-Executive Director on the board of GlaxoSmithKline Consumer Healthcare Holdings Limited between 2015-2018 and a non-executive director of the Novartis Venture Fund.
Harry holds a degree in industrial engineering and economics (Diplom-Wirtschaftsingenieur) from the University of Karlsruhe in Germany.
Skills and experience
Harry brings 35 years of financial expertise to the Board. He is a strong leader, with experience gained in large, pharmaceutical and consumer goods organisations and has a history of driving major transformation, growth and enterprise value creation.
Current External appointments
None